By Huvepharma – Bulgaria
Arguments “For” the use of Ivermectin in COVID-19
In 2020, the search for an antiviral drug that is effective against SARS-CoV-2 infection has led to mass testing of molecules in vivo and in vitro, but, unfortunately, in most cases with unconvincing or no effect. The in vitro testing of the “miracle drug” Ivermectin by Leon Caly’s team gave hope in this regard. In the experiment, Vero / hSLAM cells infected with SARS-CoV-2 isolate were exposed to 5 µM (micromoles) of the drug. Subsequently, viral replication was measured by RT-PCR on day 0 to day 3. Thus, Caly found that in just 24 hours, viral replication at these in vitro concentrations of Ivermectin decreased by 93% in the supernatant, representing the level of free virus particles, and of 99.8% in the cells, i.e. non- “packaged” and unreleased virus particles. Within 48 hours, this effect is amplified 5,000 times. The experiment found that the concentration of Ivermectin reducing viral replication by 50% (IC50) was 2 µM4.